Dual time point FDG PET for evaluation of malignant pleural mesothelioma

Nuclear Medicine Communications

Volumn 30, Issue 1, 2009, Pages 25-29

  Yamamoto, Yuka ^a   Kameyama, Reiko ^a   Togami, Taro ^a   Kimura, Naruhide ^a   Ishikawa, Shinya ^a   Yamamoto, Yasumichi ^a   Nishiyama, Yoshihiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Delayed positron emission tomography; Malignant pleural mesothelioma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 57749188724     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328310b3ba     Document Type: Article

References (19)

1. Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH Jr, Healy-Baldini E, DeCamp MM Jr, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 1996; 224:288-296.
2. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007; 45:379-387.
3. McLoud T. Conventional radiography in the diagnosis of asbestos-related disease. Radiol Clin North Am 1992; 30:1177-1189.
4. Muller N. Imaging of the pleura. Radiology 1993; 186:297-309.
5. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332.
6. Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Eur J Cardiothorac Surg 2000; 17: 377-383.
7. 18F-FDG dual-head gamma-camera coincidence imaging comparison with histopathology. J Nucl Med 2002; 43:1144-1149.
8. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003; 126:11-16.
9. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000; 120:128-133.
10. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114:713-722.
11. 18F-FDG uptake in malignant pleural mesothelioma. Thorax 2003; 58:1077-1082.
12. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999; 40:1241-1245.
13. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005; 129:1364-1370.
14. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005; 49:27-32.
15. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417.
16. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36:1301-1306.
17. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28:696-703.
18. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-875.
19. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2002; 44:540-548.